Reportedly, the company has recruited first patient in September 2010.
In the trial, the patients are expected to receive immunization over a period of six months, with the primary endpoint evaluated at month 7.
Dynavax president and chief medical officer Tyler Martin said that completion of enrollment in this trial is another important milestone in the development of Heplisav and keeps us on track for BLA submission in Q4 2011.
"We expect the last immunizations to be administered in June 2011," Martin said.